Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCK in Rheumatoid Arthritis
NCT03755258Phase 1Unknown
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Mar 2017
- Primary completion
- Jul 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ginsenoside compound k in rheumatoid arthritis (RA) (4 arms), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd. Primary endpoint: American College of Rheumatology response criteria 20 at 12 weeks. Status: unknown.
02
Drugs
ginsenoside compound k
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03755258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755258.